Placental stem cell populations
View Patent ↗The present invention provides placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. The invention also provides methods of differentiating the placental stem cells. The invention further provides methods of using the placental stem cells in assays and for transplanting.
1. A population of isolated adherent placental stem cells, wherein said stem cells:
express genes at a detectably higher level than an equivalent number of bone marrow-derived mesenchymal stem cells (BM-MSCs); wherein said genes comprise ELOVL2, ST3GAL6, ST6GALNAC5, or SLC12A8; wherein at least 70% of said placental stem cells are non-maternal in origin; and
wherein said cells have been passaged at least three times and cultured under growth conditions.
2. The population of claim 1 , wherein at least 90% of said placental stem cells are non-maternal in origin.
3. The population of claim 1 present in a form suitable for intravenous administration.
4. The population of claim 1 , wherein said cells have the capacity to differentiate into cells having characteristics of neural cells.
5. The population of claim 1 , wherein said genes further comprise CD200 and NUAK1.
6. The population of claim 1 , wherein said genes further comprise ARTS-1, IER3, IL6, KRT18, LRAP, MEST, NFE2L3, or TGFB2.
7. The population of claim 1 , wherein said expression of said genes is detectably higher level than an equivalent number of bone marrow-derived mesenchymal stem cells over 3 population doublings.
8. The population of claim 1 , wherein said expression of said genes is detectably higher level than an equivalent number of bone marrow-derived mesenchymal stem cells over 11-14 population doublings.
9. The population of claim 1 , wherein said expression of said genes is detectably higher level than an equivalent number of bone marrow-derived mesenchymal stem cells over 24-38 population doublings.
10. The population of claim 1 , wherein said population comprises at least 1 ×10 9 cells.
11. The population of claim 1 , wherein said population has undergone at least 5 population doublings.
12. The population of claim 1 , additionally comprising stem cells that are not obtained from placental tissue.
13. The population of claim 12 , wherein said stem cell not obtained from a placenta is a mesenchymal stem cell.
14. The population of claim 12 , wherein said stem cells not obtained from a placenta are hematopoietic progenitor cells.
15. The population of claim 1 , wherein said cells have been cryopreserved.
16. The population of claim 1 , wherein said cells express said one or more genes at a detectably higher level than an equivalent number of BM-MSCs in medium comprising DMEM-LG and MCDB-201; 2% fetal calf serum, 1× insulin-transferrin-selenium, 1× lenolenic-acid-bovine-serum-albumin, 10 −9 M dexamethasone, 10 −4 M ascorbic acid 2-phosphate, 10 ng/ml epidermal growth factor, and 10 ng/ml platelet derived-growth factor.
17. The population of claim 1 , wherein said placental cells have the ability to replicate 10-40 times in culture.
18. The population of claim 1 , wherein said placental cells have the ability to replicate 10-40 times in culture in DMEM and fetal bovine serum.
19. The population of claim 1 , wherein said placental cells are isolated from a human postpartum placenta by digestion using trypsin, or are cultured from cells isolated from a human postpartum placenta by digestion using trypsin.
20. The population of clam 1 , wherein said placental cells have been separated from at least 90% of cells from the placenta from which the placental cells are isolated.
21. The population of claim 1 , wherein said population comprises 1×10 8 to 5×10 8 placental stem cells.
22. The population of claim 1 , wherein said population comprises 5×10 8 to 1×10 9 placental stem cells.
23. The population of claim 1 , wherein said population comprises 1×10 9 to 5×10 9 placental stem cells.
24. The population of claim 1 , wherein said placental stem cells have been passaged 4 to 8 times.
25. The population of claim 1 , wherein said placental stem cells have been passaged 6 times.
26. The population of claim 1 , wherein said placental cells have undergone 18 to 26 population doublings.
27. The population of claim 1 , wherein said placental stem cells have a doubling time of three to five days.
28. The population of claim 1 , wherein said population is present in a composition comprising dimethylsulfoxide (DMSO), human serum albumin (HSA), or dextran.
29. The population of claim 1 , wherein said placental stem cells differentiate into cells having a characteristic of chondrogenic cells when cultured in DMEM comprising 15% cord blood serum and 0.01 μg/mL transforming growth factor beta (TGFβ); and wherein said characteristic of chondrogenic cells is positive staining with Alcian Blue stain.
30. The population of claim 1 , wherein said placental stem cells differentiate into cells having a characteristic of osteogenic cells when cultured in DMEM comprising 15% cord blood serum, 0.1 μM dexamethasone, 0.05 mM ascorbic acid-2-phosphate, and 10 mM beta glycerophosphate; and wherein said characteristic of osteogenic cells is staining with von Kossa stain or production of mRNA for alkaline phosphatase as determined by RT-PCR.
31. The population of claim 1 , wherein at least 90% of cells in the population are said placental stem cells.
32. The population of claim 1 , wherein at least 95% of cells in the population are said placental stem cells.
33. The population of claim 1 , wherein at least 99% of cells in the population are said placental stem cells.
34. The population of claim 1 , wherein said cells express said genes at least at a three-fold higher level than an equivalent number of BM-MSCs.
35. The population of claim 1 , wherein said genes comprise ELOVL2.
36. The population of claim 1 , wherein said genes comprise ST3GAL6.
37. The population of claim 1 , wherein said genes comprise ST6GALNAC5.
38. The population of claim 1 , wherein said genes comprise SLC12A8.